ABSTRACT
ABSTRACT: This review summarizes the evaluation for underlying rheumatic conditions in patients presenting with acute pericarditis, treatment considerations for specific rheumatic conditions, and the role of imaging in diagnosis and monitoring. Pericarditis may be one of the initial presentations of a rheumatic disease or identified in a patient with known rheumatic disease. There is also growing evidence for using anti-inflammatory and immunosuppressive agents for treating recurrent pericarditis, which can overlap with the treatment of rheumatic diseases.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Colchicine/therapeutic use , Pericarditis/drug therapy , Acute Disease , Aspirin/administration & dosage , Aspirin/therapeutic use , C-Reactive Protein/analysis , Colchicine/administration & dosage , Disease Management , Double-Blind Method , Drug Therapy, Combination , Electrocardiography , Glucocorticoids/therapeutic use , Hospitalization , Humans , Ibuprofen/therapeutic use , Immunosuppressive Agents , Male , Middle Aged , Pericarditis/blood , Randomized Controlled Trials as Topic , Recurrence , Troponin T/bloodSubject(s)
Echocardiography , Heart Defects, Congenital , Magnetic Resonance Imaging , Syncope/etiology , Adult , Female , Heart Defects, Congenital/complications , Heart Defects, Congenital/diagnostic imaging , Heart Defects, Congenital/pathology , Heart Ventricles/diagnostic imaging , Heart Ventricles/pathology , HumansSubject(s)
Cholesterol, HDL/blood , Cholesterol, LDL/blood , Age Factors , Female , Humans , Middle Aged , Reference Values , Risk FactorsABSTRACT
Pharmacologic therapy of lipid disorders has become an established means to reduce cardiovascular morbidity and mortality. Compared to middle-aged individuals with hyperlipidemia, the use of such treatment in the elderly population has been controversial, as there is only scant data from large clinical trials that can be applied to this group. Therefore, current recommendations for specific anti-lipid drug use in older individuals must weigh each drug's potential benefits against the potential treatment risks that are inherent to this age group.